4
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Drug repositioning identifies novel therapeutic potentials for existing drugs and is considered an attractive approach due to the opportunity for reduced development timelines and overall costs. Prior computational methods usually learned a drug's representation from an entire graph of drug-disease associations. Therefore, the representation of learned drugs representation are static and agnostic to various diseases. However, for different diseases, a drug's mechanism of actions (MoAs) are different. The relevant context information should be differentiated for the same drug to target different diseases. Computational methods are thus required to learn different representations corresponding to different drug-disease associations for the given drug. In view of this, we propose an end-to-end partner-specific drug repositioning approach based on graph convolutional network, named PSGCN. PSGCN firstly extracts specific context information around drug-disease pairs from an entire graph of drug-disease associations. Then, it implements a graph convolutional network on the extracted graph to learn partner-specific graph representation. As the different layers of graph convolutional network contribute differently to the representation of the partner-specific graph, we design a layer self-attention mechanism to capture multi-scale layer information. Finally, PSGCN utilizes sortpool strategy to obtain the partner-specific graph embedding and formulates a drug-disease association prediction as a graph classification task. A fully-connected module is established to classify the partner-specific graph representations. The experiments on three benchmark datasets prove that the representation learning of partner-specific graph can lead to superior performances over state-of-the-art methods. In particular, case studies on small cell lung cancer and breast carcinoma confirmed that PSGCN is able to retrieve more actual drug-disease associations in the top prediction results. Moreover, in comparison with other static approaches, PSGCN can partly distinguish the different disease context information for the given drug.

          Related collections

          Author and article information

          Journal
          IEEE J Biomed Health Inform
          IEEE journal of biomedical and health informatics
          Institute of Electrical and Electronics Engineers (IEEE)
          2168-2208
          2168-2194
          Nov 2022
          : 26
          : 11
          Article
          10.1109/JBHI.2022.3194891
          35921345
          6d3bc8d3-a2d4-48f3-a6f3-ed89d3089d09
          History

          Comments

          Comment on this article